Small-Cap Growth Without Dividends: What NUSC’s 1.4 Beta Really Costs Investors

Small-cap stocks have historically rewarded patient investors willing to endure volatility in exchange for growth potential. But what if you want that exposure while filtering for companies meeting environmental, social, and governance standards? That’s the exact niche the Nuveen ESG Small-Cap ETF (NASDAQ:NUSC) attempts to fill, screening the small-cap universe for ESG compliance while maintaining broad diversification.

What NUSC Brings to Your Portfolio

NUSC tracks the TIAA ESG Small-Cap Index across roughly 500 companies, creating broad diversification within the ESG-screened universe. The portfolio’s heavy concentration in Industrials and Financials creates a cyclical tilt that amplifies economic swings—when the economy expands, these sectors typically lead gains, but they also face steeper declines during downturns. This sector positioning reflects the fund’s strategy of capturing small-cap growth while maintaining ESG compliance.

The fund’s 0.31% expense ratio positions it in the middle range for ESG ETFs, reflecting the additional research required for ESG screening. Investors should note that NUSC functions as a pure growth vehicle with minimal dividend income, making it suitable for those prioritizing capital appreciation over current income.

Does ESG Screening Enhance or Hinder Returns?

NUSC’s recent performance tells a mixed story about ESG screening’s impact. The fund lagged the Russell 2000 by over 5 percentage points in the past year, suggesting ESG exclusions may have filtered out some recent winners. However, the five-year view shows NUSC ahead by roughly 5 percentage points, indicating the screening hasn’t consistently hindered returns. Since its 2016 launch, the broader small-cap market has captured more total upside, though both have delivered strong long-term gains for patient investors.

The fund’s top holdings reveal a mix of healthcare innovators like Exact Sciences (NASDAQ:EXAS | EXAS Price Prediction) and Moderna (NASDAQ:MRNA), alongside regional banks and specialty materials companies. This diversification spreads risk but also means no single position drives outsized returns. With a beta of approximately 1.4 relative to the broader market, NUSC amplifies both gains and losses compared to large-cap indexes.

The Tradeoffs You Accept

ESG screening inherently narrows your investment universe. Companies excluded for governance issues, environmental concerns, or social controversies may sometimes outperform, meaning you sacrifice potential returns for values alignment. NUSC’s sector tilts also create concentration risk during economic downturns when cyclical sectors underperform.

Small-cap volatility represents another reality. During market stress, smaller companies often experience sharper drawdowns than large-caps, and liquidity can dry up faster. The fund’s minimal dividend yield means total returns depend almost entirely on price appreciation, offering no income cushion during flat or declining markets.

NUSC works best for investors seeking long-term growth exposure to smaller companies while maintaining ESG standards, but the volatility and sector concentration require patience and a tolerance for drawdowns that can exceed broader market declines.